Podcasts about Patina

The podcast episode featured Mike Clemens, who shared the story of his 1965 Fastback Mustang from the movie "The Bucket List." Mike explained how the car was purchased for the film and later sold, only to be reacquired 15 years later. He detailed the car's modifications for the movie, including a roll bar and square tube steel for the sideswipe scene. Mike also discussed his passion for classic Mustangs, having owned three similar cars before this one. The episode concluded with a discussion about the potential for renting classic cars for various productions and events.Bucket List Race Scene: https://youtu.be/mtZR_5sBqmI?si=XCZ_ZDlGypH18jqkConnect with the show:@mustangpodcasthttps://www.instagram.com/mustangpodcast/Interested in renting your Classic Ride for photo shoots?ClassicFordRentals.comGot a classic Ford in SoCal? A Mustang. F-Series, or Classic Falcon or Galaxy? Survivor? Showing lots of Patina? Or a Show truck. I'm looking to put real classics on real sets — photo shoots, commercials, film, and premium productions. You keep your ride. I handle the clients, bookings, and logistics. Turn your classic Ford into a paid, on-camera icon.Visit ClassicFordRentals.com, scroll to the bottom of the page, and share your info with me— let's get your truck or Mustang working.An Expert's Guide to Maintaining Your Classic Mustangwww.TheMustangPodcast.com/repairSponsored by: National Parts Depotwww.npdlink.comWith 4 warehouses nationwide, you'll get your parts fast!Email Doug: doug@turnkeypodcast.com"Keep it safe, keep it rollin', and keep it on the road. Until next time!" Doug SandlerRent your Classic Ford for commercials, film and special eventswww.ClassicFordRentals.comSign up today free of charge

Well, if you let Jon off the leash, you get X thing that isn't Star Wars, so I guess we shouldn't be surprised we're reading about Mulder and Scully now. And some archaeologist named Cassandra Rubicon who you simply must know is incredibly hot, it is vital. Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode of the Oncology Brothers podcast, we dived deep into the evolving landscape of HER2-positive breast cancer treatment following the significant advancements made in 2025. Joined by Dr. Virginia Kaklamani from UT Health San Antonio, we discussed the latest data from SABCS 2025 and pivotal trials such as DESTINY-Breast09, which have led to new treatment approvals and strategies. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Key topics included: • The treatment algorithm for early-stage HER2-positive breast cancer, including the APT trial and the role of trastuzumab. • Insights into neoadjuvant and adjuvant therapies, including the implications of the neoCARHP trial regimen and the potential of T-DXd. • The impact of recent studies in metastatic HER2-positive disease, including the approval of T-DXd plus pertuzumab and the promising results from the PATINA trial. • A discussion on managing side effects and the importance of patient quality of life during treatment. Join us for an informative conversation that highlights the latest advancements in HER2-positive breast cancer care and how they can be applied in clinical practice. Don't forget to like, subscribe, and leave a review to help us reach more healthcare professionals who can benefit from these discussions! #HER2Positive, #BreastCancer, #SABCS25, #TDXd, #BreastCancerTreatment, #OncologyBrothers

The Patina regroups and brings out the big guns.Cast: - Marathon Messenger is played by Penn Van Batavia. She can be found on Twitter at @acquiredchaste and in drag as horror king JOHN on Instagram at @john.is.risen. Penn is an indie TTRPG designer whose most recent work includes SLICE *IT* OUT, a grisly carving RPG about cutting pieces of yourself out to fit in. Check out faer other work at pennharper.itch.io. - Cassidy Shard is played by Sydney Whittington. She is our wonderful editor. She's also a contributing editor and occasional guest player for the Orpheus Protocol, a cosmic horror espionage actual play podcast. Find her on Twitter at @sydney_whitt. - Emma Blackwood is played by Cameron Robertson. Find her on Twitter at @midnightmusic13 and on Instagram at @reading_and_dreaming. Cameron is also a player on Tabletop Squadron, a Star Wars Edge of the Empire actual play podcast. - Birdie Foundling is played by Kit Adames. Find her on Twitter at @venusvultures. Kit is also a voice actor and writer on Elevator Pitch Podcast, a queer genre-hopping anthology podcast that can be accessed on Spotify and YouTube. - Our GM and narrator is Nick Robertson. Find him on Twitter at @alias58. Nick is also the GM for Tabletop Squadron and can also be found as a player on the Orpheus Protocol.Music & Sound Credits: - This podcast features the musical talents of Dora Violet and Arne Parrott. You can find Dora at facebook.com/doraviolett. You can find Arne at atptunes.com. - old radio Channel search sound effect by Garuda1982. Link & License. - Memories in Love (ID 1144) by Lobo Loco. Link & License. - Carrot Sticks by Doctor Turtle. Link & License.Art Credits: - The official artwork for this podcast was created by Rashed AlAkroka, who can be found on Instagram and Artstation @rashedjrs.Find Us Online: - Our Website - Twitter - Join our Patreon - Join our Discord

Confira os destaques olímpicos do quinto dia de jogos olímpicos de inverno! Destacando Patinação Artística, Hóquei, Patinação em Velocidade e muito mais!

Confira os destaques olímpicos do quinto dia de jogos olímpicos de inverno! Destacando Patinação Artística, Hóquei, Patinação em Velocidade, Snowboard e muito mais!

Confira os destaques olímpicos do quinto dia de jogos olímpicos de inverno! Destacando Patinação Artística, Hóquei, Patinação em Velocidade e muito mais!

Confira os destaques olímpicos do quinto dia de jogos olímpicos de inverno! Destacando Patinação Artística, Patinação em Velocidade, Hóquei e muito mais!

Got a classic Ford in SoCal? Mustang. F-Series. Survivor. Patina. Show truck. I'm looking to put real classics on real sets — photo shoots, commercials, film, and premium productions. You keep your ride. I handle the clients, bookings, and logistics. Turn your classic Ford into a paid, on-camera icon.Visit ClassicFordRentals.com, scroll to the bottom of the page, and share your info with me— let's get your truck or Mustang working.Now, onto today's guest. What could be more fun than one Classic Mustang? TWO!! Here to share her Mustang story and how she got into a 1965 and a 1972 pony, welcome Jen Ketrow to Ford Mustang The Early Years Podcast.Connect with the show:@mustangpodcasthttps://www.instagram.com/mustangpodcast/An Expert's Guide to Maintaining Your Classic Mustangwww.TheMustangPodcast.com/repairSponsored by: National Parts Depotwww.npdlink.comWith 4 warehouses nationwide, you'll get your parts fast!Email Doug: doug@turnkeypodcast.com"Keep it safe, keep it rollin', and keep it on the road. Until next time!" Doug SandlerRent your Classic Ford for commercials, film and special eventswww.ClassicFordRentals.comSign up today free of charge

Hello dear listener, Welcome back! This week, I'm joined by my trusty sidekick, Matt Knight, and we're talking all about the new affordable Nitro Finished guitars from Patina Guitars! Hosted on Acast. See acast.com/privacy for more information.

Confira os destaques olímpicos do segundo dia de jogos olímpicos de inverno. Entre eles Hóquei, Curling e a disputa por equipes da Patinação Artística!

 Confira os destaques olímpicos do terceiro dia de jogos olímpicos de inverno. Entre eles Curling,a disputa por equipes da Patinação Artística e acidente grave ao longo das competições do dia. 

Confira os destaques olímpicos dos dias pré-abertura dos jogos e todos os detalhes do primeiro dia de jogos. Entre eles Hóquei, Curling e a disputa por equipes da Patinação Artística!

The Patina battles mercenaries and unravels the heart of Sasnak Traveling.Cast: - Marathon Messenger is played by Penn Van Batavia. She can be found on Twitter at @acquiredchaste and in drag as horror king JOHN on Instagram at @john.is.risen. Penn is an indie TTRPG designer whose most recent work includes SLICE *IT* OUT, a grisly carving RPG about cutting pieces of yourself out to fit in. Check out faer other work at pennharper.itch.io. - Cassidy Shard is played by Sydney Whittington. She is our wonderful editor. She's also a contributing editor and occasional guest player for the Orpheus Protocol, a cosmic horror espionage actual play podcast. Find her on Twitter at @sydney_whitt. - Emma Blackwood is played by Cameron Robertson. Find her on Twitter at @midnightmusic13 and on Instagram at @reading_and_dreaming. Cameron is also a player on Tabletop Squadron, a Star Wars Edge of the Empire actual play podcast. - Birdie Foundling is played by Kit Adames. Find her on Twitter at @venusvultures. Kit is also a voice actor and writer on Elevator Pitch Podcast, a queer genre-hopping anthology podcast that can be accessed on Spotify and YouTube. - Our GM and narrator is Nick Robertson. Find him on Twitter at @alias58. Nick is also the GM for Tabletop Squadron and can also be found as a player on the Orpheus Protocol.Music & Sound Credits: - This podcast features the musical talents of Dora Violet and Arne Parrott. You can find Dora at facebook.com/doraviolett. You can find Arne at atptunes.com. - old radio Channel search sound effect by Garuda1982. Link & License. - gunshot.wav by mark646. Link & License. - " Bangs and Explosions » Explosion_001.mp3 " by cydon. Link & License. - Sundial_Bridge_03_cable_13.flac by DAAyer. Link & License. - The Leopard by Julia Kent. Link & License. - Long Story by Sergey Cheremisinov. Link & License.Art Credits: - The official artwork for this podcast was created by Rashed AlAkroka, who can be found on Instagram and Artstation @rashedjrs.Find Us Online: - Our Website - Twitter - Join our Patreon - Join our Discord

Fabian Freytag zählt zu den spannendsten Stimmen des zeitgenössischen Interior Designs: furchtlos, verspielt und radikal eigen. Seine Räume sind keine Kompositionen aus Regeln, sondern aus Mut, Emotion und Geschichten, die sich jeder zeitlichen Einordnung entziehen. Wie entsteht Wohnen, das sich der zeitlichen Zuordnung entzieht und trotzdem voller Gegenwart steckt? Welches Feld eröffnet sich hier für tiefe Erzählungen, individuelle Logiken und das Erforschen dessen, was Menschen in ihren Räumen wirklich brauchen? Welche Rolle spielen Patina, Vintage und die Freude am Unperfekten und warum enthält der entschiedene Mix oft mehr Wahrheit als perfekte Ordnung? Darüber sprechen wir heute im JUNG Talk Podcast mit Fabian Freytag: über Räume, die leben, überraschen und berühren, und darüber, warum man manchmal einfach „dem weißen Hasen folgen“ sollte. Und natürlich über die KI, die für ihn kein Feind ist, sondern ein kreativer Urknall, der das Design in neue ästhetische Sphären katapultiert.

Reviewing the hot-off-the press publication of PATINA, palbociclib in HER-2 amplified breast cancer along with endocrine therapy and HER-2 targeted antibodies.

The Patina continues trying to save Sasnak Traveling while simultaneously dismantling the city's innermost security protocols.Cast: - Marathon Messenger is played by Penn Van Batavia. She can be found on Twitter at @acquiredchaste and in drag as horror king JOHN on Instagram at @john.is.risen. Penn is an indie TTRPG designer whose most recent work includes SLICE *IT* OUT, a grisly carving RPG about cutting pieces of yourself out to fit in. Check out faer other work at pennharper.itch.io. - Cassidy Shard is played by Sydney Whittington. She is our wonderful editor. She's also a contributing editor and occasional guest player for the Orpheus Protocol, a cosmic horror espionage actual play podcast. Find her on Twitter at @sydney_whitt. - Emma Blackwood is played by Cameron Robertson. Find her on Twitter at @midnightmusic13 and on Instagram at @reading_and_dreaming. Cameron is also a player on Tabletop Squadron, a Star Wars Edge of the Empire actual play podcast. - Birdie Foundling is played by Kit Adames. Find her on Twitter at @venusvultures. Kit is also a voice actor and writer on Elevator Pitch Podcast, a queer genre-hopping anthology podcast that can be accessed on Spotify and YouTube. - Our GM and narrator is Nick Robertson. Find him on Twitter at @alias58. Nick is also the GM for Tabletop Squadron and can also be found as a player on the Orpheus Protocol.Music & Sound Credits: - This podcast features the musical talents of Dora Violet and Arne Parrott. You can find Dora at facebook.com/doraviolett. You can find Arne at atptunes.com. - old radio Channel search sound effect by Garuda1982. Link & License. - gunshot.wav by mark646. Link & License. - Centerfire_Rifle_Gun_Shot_01.wav by MATRIXXX_. License. - Sword Shing 19 by Department64. Link & License. - White Atlantis by Sergey Cheremisinov. Link & License. - The Signals by Sergey Cheremisinov. Link & License.Art Credits: - The official artwork for this podcast was created by Rashed AlAkroka, who can be found on Instagram and Artstation @rashedjrs.Find Us Online: - Our Website - Twitter - Join our Patreon - Join our Discord

Das Schlagzeug sorgt im Jazz für den Puls, für den Drive – es ist der Herzschlag der Musik. Aber immer mehr Drummer sind nicht nur Begleiter, die gelegentlich ein kurzes Solo beisteuern, sondern auch Bandleader und Komponisten. Diese Entwicklung der letzten Jahre lässt sich ebenfalls beim jungen Drummer Jonas Sorgenfrei aus Nürnberg beobachten. Er ist Bandleader, Komponist und sensibler Schlagzeuger. Auf seinem fünften Album „Cracks In The Silence“ präsentiert er eine enorme musikalische Vielfalt und ganz unterschiedliche Stimmungen – intime, lyrische Titel stehen neben kraftvollen Ensemblestücken, und immer stärker wird das Klangbild von einer elektronischen Patina überzogen. „Die ‚Risse in der Stille' sind eine schöne Metapher für die reifen, aber doch überraschenden Performances auf diesem Album“ – meint unser Jazzkritiker Niklas Wandt.

After reaching the core, the Patina rebandages wounds and begins their task of hacking into the city.Cast: - Marathon Messenger is played by Penn Van Batavia. She can be found on Twitter at @acquiredchaste and in drag as horror king JOHN on Instagram at @john.is.risen. Penn is an indie TTRPG designer whose most recent work includes SLICE *IT* OUT, a grisly carving RPG about cutting pieces of yourself out to fit in. Check out faer other work at pennharper.itch.io. - Cassidy Shard is played by Sydney Whittington. She is our wonderful editor. She's also a contributing editor and occasional guest player for the Orpheus Protocol, a cosmic horror espionage actual play podcast. Find her on Twitter at @sydney_whitt. - Emma Blackwood is played by Cameron Robertson. Find her on Twitter at @midnightmusic13 and on Instagram at @reading_and_dreaming. Cameron is also a player on Tabletop Squadron, a Star Wars Edge of the Empire actual play podcast. - Birdie Foundling is played by Kit Adames. Find her on Twitter at @venusvultures. Kit is also a voice actor and writer on Elevator Pitch Podcast, a queer genre-hopping anthology podcast that can be accessed on Spotify and YouTube. - Our GM and narrator is Nick Robertson. Find him on Twitter at @alias58. Nick is also the GM for Tabletop Squadron and can also be found as a player on the Orpheus Protocol.Music & Sound Credits: - This podcast features the musical talents of Dora Violet and Arne Parrott. You can find Dora at facebook.com/doraviolett. You can find Arne at atptunes.com. - old radio Channel search sound effect by Garuda1982. Link & License. - Labyrinth by Sergey Cheremisinov. Link & License. - What Is It I Know by The Oracle Of St. Vincent. Link & License.Art Credits: - The official artwork for this podcast was created by Rashed AlAkroka, who can be found on Instagram and Artstation @rashedjrs.Find Us Online: - Our Website - Twitter - Join our Patreon - Join our Discord

Dr. Monty Pal and Dr. Hope Rugo discuss advances in antibody-drug conjugates for various breast cancer types as well as treatment strategies in the new era of oral SERDs for HR-positive breast cancer. TRANSCRIPT Dr. Monty Pal: Hello, and welcome to the ASCO Daily News Podcast. I'm your host, Dr. Monty Pal. I'm a medical oncologist and vice chair of academic affairs here at the City of Hope Comprehensive Cancer Center, Los Angeles. Today, I'm thrilled to be joined by Dr. Hope Rugo, an internationally renowned breast medical oncologist and my colleague here at City of Hope, where she leads the Women's Cancers Program and serves as division chief of breast medical oncology. Dr. Rugo is going to share with us exciting advances in antibody-drug conjugates (ADCs) that are expanding treatment options in various breast cancer types. She'll also address some of the complex questions arising in the new era of oral SERDs (selective estrogen receptor degraders) that are revolutionizing treatment in the hormone receptor-positive breast cancer space. Our full disclosures are available in the transcript of this episode.  Dr. Rugo, welcome, and thanks so much for being on the podcast today. Dr. Hope Rugo: Thank you. Pleasure to be here. Dr. Monty Pal: So, I'm going to switch to first names if you don't mind.  The first topic is actually a really exciting one, Hope, and this is antibody-drug conjugates. I don't know if I've ever shared this with you, but I actually started my training at UCLA, I was a med student and resident there, and it was in Dennis Slamon's lab. I worked very closely with Mark Pegram and a handful of others. This is right around the time I think a lot of HER2-directed therapies were really evolving initially in the clinics. Now we've got antibody-drug conjugates. Our audience is well-familiar with the mechanism there but tell us about how ADCs have really started to reshape therapy for HER2-positive breast cancer. Dr. Hope Rugo: Yeah, I mean, this is a really great place to start. I mean, we have had such major advances in breast cancer just this year, I think really changing the paradigm of treating patients. But HER2-positive disease, we've been used to having sequenced success of new agents. And I think the two biggest areas where we've made advances in HER2-positive disease, which were remarkably advanced this year in 2025, have been in antibody-drug conjugates with trastuzumab deruxtecan and with new oral tyrosine kinase inhibitors (TKIs) that have less of a target on EGFR and more on HER2, so they have an overall more tolerable toxicity profile and therefore a potentially better efficacy in the clinic. At least that's what we're seeing with these new strategies that we couldn't really pursue in the past because of toxicities of the oral TKIs. So, although our topic is ADCs, I'm going to include the TKI because it's so important in our thinking about treating HER2-positive disease. In the metastatic setting, we've seen these remarkable improvements in progression-free and overall survival in the second-line setting with T-DXd, or trastuzumab deruxtecan, compared to T-DM1. And then sequencing ADCs with giving T-DXd after T-DM1 was better than an oral tyrosine kinase or a trastuzumab combination with standard chemotherapy. That was DESTINY-Breast03 and DESTINY-Breast02. So, then we've had other trials since then, and T-DXd has moved into the early-stage setting, which I'll talk about in just a moment. But the next big trial for T-DXd in HER2-positive disease was moving it to the first-line setting to supplant what has become an established treatment for now quite a long time: the so-called CLEOPATRA regimen, which used the combined antibodies trastuzumab, pertuzumab with a taxane as first-line therapy. And then we've proceeded on with maintenance with ongoing HP for patients with responding or stable disease. And we'd seen long-term data showing, you know, at 8 years there was a group of patients whose cancers had never progressed and continued improved overall survival. So, T-DXd was studied in DESTINY-Breast09, either alone or in combination with pertuzumab compared to THP. The patient population had received a little bit more prior treatment, but interestingly, not a lot compared to CLEOPATRA. And they designed the trial to be T-DXd continued until progression with or without pertuzumab versus THP, which would go for six cycles and then stop around six cycles, and then stop and continue HP. Patients who had hormone receptor-positive disease could use hormone therapy, and this is one of the issues with this dataset because, surprisingly in this dataset and one other I'll mention, very few patients took hormone therapy. And even in the maintenance trial, the HER2CLIMB-05, less than 50% took hormone therapy as maintenance. This is kind of shocking to me and highlights an area of really important education, that outcome is improved when you add endocrine therapy for hormone receptor-positive HER2-positive metastatic disease in the maintenance phase, and it's a really important part of treatment. But suffice it to say, you know, you're kind of studying continued chemo versus stopping chemo in maintenance. And T-DXd, as we all expected, in combination with pertuzumab was superior to THP in terms of progression-free survival, really remarkably improved. And you could stop the chemo with toxicity, but most people continued it with T-DXd. Again, not a lot of people got hormone therapy, which is an issue, and you stop the chemo in the control arm. So, this has brought up a lot of interest in trying to use T-DXd as an induction and then go to maintenance, much as we do with the CLEOPATRA regimen with hormone therapy. But it brings up another issue. So first, T-DXd is superior; it's a great treatment. Not everybody needs to have it because we don't know whether it's better to give T-DXd first or second with progression - that we need a little bit longer follow-up. But just earlier this week, interestingly, the third week of December, the U.S. FDA approved T-DXd in the DESTINY-Breast09 approach with pertuzumab. So as I mentioned earlier, there was a T-DXd-alone arm; that arm has not yet reported. So very interesting, we don't know if you need pertuzumab or not. So what about the maintenance? That's the other area where we've made a huge advance here. So, we all want to stop chemo and we want to stop T-DXd. You don't want somebody being nauseated for two years while they're on treatment, and also there's a small number of patients with mostly de novo metastatic HER2-positive disease who are cured of their disease. We'd like to expand that, and I think these new drugs give us the opportunity to improve the number of patients who might be cured from metastatic disease. So the first maintenance study we saw was adding palbociclib, the CDK4/6 inhibitor, to endocrine therapy and HP, essentially. There, we had a remarkable improvement in progression-free survival difference of 15.2 months: 29 to 44 months, really huge. At San Antonio this year, we saw data with this oral tyrosine kinase inhibitor tucatinib, already showed it was great in a triplet, but as maintenance in combination with HP, it showed also a remarkable improvement in progression-free survival. But the numbers were all shifted down. So in PATINA, the control arm was in the 24-month range; here it was the tucatinib-HP arm that was in the 25 months and 16 months for control. So there was a differential benefit in ER-negative and ER-positive disease. So I think we're all thinking that our ideal approach moving forward would be to give T-DXd to most patients, we see how they do, and treat to best response. And then, stop the T-DXd, start HP, trastuzumab, pertuzumab for ER-negative, with tucatinib for ER-positive with palbociclib. We also have early data that suggests that both approaches may reduce the development of brain metastases, an issue in HER2-positive disease, and delay time to progression of brain metastases as seen in HER2CLIMB-05 in very early data - small numbers, but still quite intriguing that you might delay progression of brain metastases with tucatinib that clearly has efficacy in the brain.  So, I think that this is a hugely exciting advance for our patients, and these approaches are quickly moving into the early stage setting. T-DXd compared to standard chemo, essentially followed by THP, so a sequenced approach resulted in more pathologic complete responses than a standard THP-AC-type neoadjuvant therapy. T-DXd alone for eight cycles wasn't better, and that's interesting. We still need the sequenced non-cross-resistant chemo. But I think even more importantly, the data from DESTINY-Breast05 looking at T-DXd versus T-DM1 in patients with residual disease after neoadjuvant HER2-targeted therapy showed a remarkable improvement in invasive disease-free survival with T-DXd versus T-DM1, and quite early. It was a high-risk population, higher risk than the T-DM1 trial with KATHERINE, but earlier readout with a remarkable improvement in outcome. We expect to be FDA approved sometime in the first half of 2026. So then we'll get patients who've already had T-DXd who get metastatic disease. But my hope is that with T-DXd, maybe with tucatinib in the right group of patients or even sequenced in very high-risk disease, that we could cure many more patients with early-stage HER2-positive breast cancer and cure a subset, a greater subset of patients with de novo metastatic disease. Dr. Monty Pal: That's brilliant. And you tackled so many questions that I was going to follow up with there: brain metastases, etc. That was sort of looming in my mind. I mean, general thoughts on an ADC versus a TKI in the context of brain mets? Dr. Hope Rugo: Yeah, it's an interesting question because T-DXd has shown quite good efficacy in this setting. And tucatinib, of course, had a trial where they took patients with new brain mets, so a larger population than we've seen yet for the T-DXd trials, and saw that not only did they delay progression of brain metastases and result in shrinkage of existing untreated brain mets, but that patients who develop a new brain met, they could stay on the same assigned treatment. They got stereotactic radiation, and then the patients who were on tucatinib with trastuzumab and capecitabine had a further delay in progression of brain mets compared to those on the placebo arm, even after treatment of a new one that developed on treatment. So, I think it's hard. I think most of us for a lot of brain mets might start with the tucatinib approach, but T-DXd is also a very important treatment. You know, you're kind of trading off a diarrhea, some liver enzyme elevations with tucatinib versus nausea, which you really have to work on managing because it can be long-delayed nausea, and this risk of ILD, interstitial lung disease, that's about 12%, with most but not all trials showing a mortality rate from interstitial lung disease of just under 1 percent. In the early-stage setting, it was really interesting to see that with T-DXd getting four cycles in the neoadjuvant setting, a lot less ILD noted than the patients who got up to 14 cycles, as I think they got a median of 10 cycles in the post-surgical setting, there was a little bit more ILD. But I think we're going to be better and better at finding this earlier and preventing mortality by just stopping drug and treating earlier with steroids. Dr. Monty Pal: And this ILD issue, it always seems to resurface. There are drugs that I use in my kidney cancer clinic, everolimus, common to perhaps the breast cancer clinic as well, pembrolizumab, where I think the pattern of pneumonitis is quite different, right? What is your strategy for recognizing pneumonitis early in this context? Dr. Hope Rugo: Well, it is, and you know, having done the very early studies in everolimus where we gave it in the neoadjuvant setting and we're like, "Hmm, the patient came in with a cough. What's going on?" You know, we didn't know. And you have mouth sores, you know, we were learning about the drug as we were giving it. What we don't do with everolimus and CDK4/6 inhibitors, for example, is grade 1 changes like radiation pneumonitis, we don't stop, we don't treat it. We only treat for symptoms. But because of the mortality associated with T-DXd, albeit small, we stop drug for grade 1 imaging-only asymptomatic pneumonitis, and some of us treat with a half dose of steroids just to try and hasten recovery. We've actually now published or presented a couple of datasets from trials, a pooled analysis and a real-world analysis, that have looked at patients who were retreated after grade 1 pneumonitis or ILD and tolerated drug very well and none of them died of interstitial lung disease, which was really great to see because you can retreat safely and some of these patients stayed on for almost a year benefiting from treatment. So, there's a differential toxicity profile with these drugs and there are risk factors which clearly have identified those at higher risk: prior ILD, for example. A French group said smoking; other people haven't found that, maybe because they smoked more in France, I don't know. And being of Japanese descent is quite interesting. The studies just captured that you were treated in Japan, but I think it's probably being of Japanese descent with many drugs that increases your risk of ILD. And, you know, older patients, people who have hypoxia, those are the patients. So, how do we do this? With everolimus, we don't have specific monitoring. But for T-DXd we do; we do every nine weeks to start with and then every 12 weeks CT scans because most of the events occur relatively early. Somebody who's older and at higher risk now get the first CT at six weeks. Dr. Monty Pal: This is super helpful. And I have to tell you, a lot of these drugs are permeating the bladder cancer space which, you know, is ultimately going to be a component of my practice, so thank you for all this. We could probably stay on this topic of HER2-positive disease forever. I'm super interested in that space still. But let me shift gears a little bit and talk about triple-negative breast cancer and this evolving space of HR-positive, HER2-low breast cancer. I mean, tell us about ADCs in that very sort of other broad area. Dr. Hope Rugo: So triple-negative disease is the absolute hardest subset of disease that we have to treat because if you don't have a great response in the early stage setting, the median survival is very short, you know, under two years for the majority of TNBCs, with the exception of the small percentage of low proliferative disease subsets. The co-question is what do we do for these patients and how do we improve outcome? And sacituzumab govitecan has been one strategy in the later line setting that was shown to improve progression-free and overall survival, the Trop-2 ADC. We had recently three trials presented with the two ADCs, sacituzumab govitecan and the other Trop-2 ADC that's approved for HR-positive disease, datopotamab deruxtecan. And they were studied in the first-line setting. Two trials with SG, sacituzumab govitecan, those trials, one was PD-L1 positive, ASCENT-04. That showed that SG with a checkpoint inhibitor was superior, so pembrolizumab was superior to the standard KEYNOTE-355 type of treatment with either a taxane or gemcitabine and carboplatin with pembrolizumab for patients who have a combined positive score for PD-L1, 10 or greater. So, these are patients who are eligible for a checkpoint inhibitor, and SG resulted in an improved progression-free survival.  The interesting thing about that dataset is that few patients had received adjuvant or neoadjuvant checkpoint inhibitor, which is fascinating because we give it to everybody now. But access is an issue and timing of the study enrollment was an issue. The other thing which I think we've all really applauded Gilead for is that there was automatic crossover. So, you could get from the company, to try and overcome some of the enormous disparities worldwide in access to these life-saving drugs, you could get SG through the company for free once you had blinded independent central review confirmation of disease progression. Now, a lot of the people who got the SG got it through their insurance, they didn't bill the company, but 80 percent of patients in the control arm received SG in the second-line setting. So that impacts your ability to look at overall survival, but it's an incredibly important component of these trials. So then at ESMO, we saw the data from SG and Dato-DXd in the first-line metastatic setting for patients who either had PD-L1-negative disease or weren't eligible for an immunotherapy. For the Dato study, TROPION-Breast02, that was 10 percent of the patients who had PD-L1-positive disease but didn't get a checkpoint inhibitor, and for the ASCENT-03 trial population it was only 1 percent. Importantly, the trials allowed patients who relapsed within a year of receiving their treatment with curative intent, and the Dato study, TB-02, allowed patients who relapsed while on treatment or within the first six months, and that was 15 percent of the 20 percent of early relapsers. The ASCENT trial, ASCENT-03, had 20 percent who relapsed between 6 and 12 months. The drugs were better than standard of care chemotherapy, the ADCs in both trials, which is very nice. Different toxicity profiles, different dosing intervals, but better than standard of care chemotherapy in the disease that's hardest for us to treat. And importantly, when you looked at the subset of early relapsers, those patients also did better with the ADC versus chemotherapy, which is incredibly important. And we were really interested in that 15 percent of patients who had early relapse. I actually think that six months thing was totally contrived, invented, you know, categorization and doesn't make any sense, and we should drop it. But the early relapsers were 15 percent of TB-02 and Dato was superior to standard of care chemo. We like survival, but the ASCENT trial again allowed the crossover to an approved ADC that improved survival and 80 percent of patients crossed over. In the Dato trial, they did not allow crossover, they didn't provide Dato, which isn't approved for TNBC but is for HR-positive disease, and they didn't allow, of course, pay for SG. So very few patients actually crossed over in their post-treatment data and in that study, they were able to show a survival benefit. So actually, I think in the U.S. where we can use approved drugs already before there's a fixed FDA approval, that people are already switching to use SG or Dato in the first-line setting for metastatic TNBC that's both PD-L1 positive for SG and PD-L1 negative for both drugs. And I think understanding the toxicity profiles of the two drugs is really important as well as the dosing interval to try and figure out which drug to use. Dr. Monty Pal: Brilliant. Brilliant. Well, I'm going to shift gears a little bit. ADCs are a topic, again, just like HER2-positive disease we could stay on forever. Dr. Hope Rugo: Huge. Yes. Dr. Monty Pal: But we're going to shift gears to another massive topic, which is oral SERDs. In broad strokes, right, this utilization of CDK4/6 inhibitors in the context of HR-positive breast cancer is obviously, you know, a paradigm that's been well established at this point. Where do we sequence in oral SERDs? Where do they fit into this paradigm? Dr. Hope Rugo: Ha! This is a rapidly changing area; we keep changing what we're saying every other minute. And I think that there are three areas of great interest. So one is patients who develop ESR1 mutations that allow constitutive signaling through the estrogen receptor, even when there's not estrogen around, and that is a really important mutation that is subclonal; it develops under the pressure of treatment in about 40 percent of patients. And it doesn't happen when you first walk in the door. And what we've seen is that oral SERDs as single agents are better than standard single-agent endocrine therapy in that setting. The problem that we've had with that approach is that we're now really interested in giving targeted agents with our endocrine therapies, not just in the first-line setting where CDK4/6 inhibitors are our standard of care with survival benefit for ribociclib and, you know, survival benefit in subsets with other CDK4/6 inhibitors, and abemaciclib with a numeric improvement. So we give it first line. The question is, what do you do in the second-line setting? Because of the recent data, we now believe that oral SERDs should be really given with a targeted agent. And some datasets which were recently presented, which I think have helped us with that, have been EMBER-3 and then the most recently evERA BC, or evERA Breast Cancer, that looked at the oral SERD giredestrant with everolimus compared to standard of care endocrine therapy with everolimus, where 100 percent of patients received prior CDK4/6 inhibitor and showed a marked improvement in progression-free survival, including in the subsets of patients with a short response, 6-12 months of prior response to CDK4/6 inhibitor and in those who had a PIK3CA pathway mutation. The thing is that the benefit looks like it's much bigger in the ESR1 mutant population, although response was better, PFS wasn't better in the wild type. So, we're still trying to figure that out. We also saw EMBER-3 with imlunestrant and abemaciclib as a second line. Not everybody had had a prior CDK4/6 inhibitor; they compared it to imlunestrant alone, but still the data was quite striking and seemed to cross the need for ESR1 mutations. And then lastly, we saw data from the single arms of the ELEVATE trial looking at elacestrant with everolimus and abemaciclib and showed these really marked progression-free survival data, even though single-arm, that crossed the mutation status. At least for the everolimus combination, abemaciclib analysis is still to come in the mutated subgroups. But really remarkable PFS, much longer.  Single-agent fulvestrant after CDK4/6 inhibitor AI has a PFS in like the three-month range and in some studies, maybe close to five months. These are all at 10-plus months and really looking very good. And so those questions are, is it ESR1 mutation alone? Is it all comers? We'd like all comers, right? We believe in the combination approach and we're learning more about combinations with drugs like capivasertib and other drugs as we move forward. Everybody now wants to combine their targeted agent with an oral SERD because they're clearly here to stay with quite remarkable data. The other issue, so the second issue in the metastatic setting is, does it make a difference if we change to an oral SERD before radiographic imaging evidence of progression? And that was the question asked in the SERENA-6 trial where patients had serial monitoring for the presence of ESR1 mutations in ctDNA. And those who had them without progression on imaging could be randomized to switch to camizestrant with the same CDK4/6 inhibitor or stay on their same AI CDK4/6 inhibitor. And they showed a difference in progression-free survival that markedly favored camizestrant. But interestingly, the people who were on the standard control arm had an ESR1 mutation, we think AIs don't work, they stayed on for nine more months. The patients who were on the camizestrant stayed on for more than 16 months. And they presented some additional subset data which showed the same thing: follow-up PFS data, PFS2, all beneficial in SERENA-6 at the San Antonio [Breast Cancer Symposium]. So, we're still a little bit unclear about that. They did quality of life, and pain was markedly improved. They had a marked delayed time to progression of pain in the camizestrant arm. So this is all a work in progress, trying to understand who should we switch without progression to an oral SERD based on this development of this mutation that correlates with resistance. And, you know, it's interesting because the median time to having a mutation was 18 months and the median time to switch was almost 24 months. And then there were like more than 3,000 patients who hadn't gotten a mutation, hadn't switched, and were still okay. So screening everybody is the big question, and when you would start and who you would change on and how this affects outcome. Patients didn't have access to camizestrant in the control arm, something we can't fix but we have experimental drugs. We're actually planning a trial, I hope in collaboration with the French group Unicancer, and looking at this exact question. You know, if you switch and you change the CDK4/6 inhibitor and then you also allow crossover, what will we see? Dr. Monty Pal: We're coming right to the tail end of our time here, and I could probably go on for another couple of hours with you here. But if you could just give us maybe one or two big highlights from San Antonio, any thoughts to leave our audience with here based on this recent meeting? Dr. Hope Rugo: Yeah, I mean, I talked about a lot of those new data already from San Antonio, and the one that I'd really like to mention which I think was, you know, there were a lot of great presentations including personalized screening presented from the WISDOM trial by my colleague Laura Esserman, fascinating and really a big advance. But lidERA was the big highlight, I think, outside of the HER2CLIMB-05 which I talked about earlier in HER2-positive disease. And this study looked at giredestrant, the oral SERD versus standard of care endocrine therapy as treatment for medium and high-risk early-stage breast cancer. And what they showed, which I think was really remarkable with just about a three-year median follow-up, was an improvement in invasive disease-free survival with a hazard ratio of 0.7. I mean, really quite remarkable and so early. It looked as though this was all driven by the high-risk group, which makes sense, not the medium risk, it's too early. And also that there was a bigger benefit in patients who were on tamoxifen compared to giredestrant versus AI, but for both groups, the confidence intervals didn't cross 1. There's even a trend towards overall survival, even though it's way too early. I think that, you know, really well-tolerated oral drug that could improve outcome in early-stage disease, this is the first advance we've seen in over two decades in the treatment of early-stage hormone receptor-positive disease with just endocrine therapy. I think we think that we don't want to give up CDK4/6 inhibitors because we saw a survival benefit with abemaciclib and a trend with giving ribociclib in the NATALEE trial. So we're thinking that maybe one approach would be to give CDK4/6 inhibitors and then switch to an oral SERD or to have enough data to be able to give oral SERDs with these CDK4/6 inhibitors for early-stage disease. And that's all in the works, you know, lots of studies going on. We're going to see a lot of data with both switching 8,000 patients with an imlunestrant switching trial, an elacestrant trial going on, and safety data with giredestrant with abemaciclib and soon to come ribociclib. So, this is going to change everything for the treatment of early-stage breast cancer, and I hope cure more patients of the most common subset of the most common cancer diagnosed in women worldwide. Dr. Monty Pal: Super exciting. It's just remarkable to hear how this has evolved since 25 years ago, which is really the last time I sort of dabbled in breast cancer.  Thank you so much, Hope, for joining us today. These were fantastic insights. Appreciate you being on the ASCO Daily News Podcast and really want to thank you personally for your remarkable contribution to the field of breast cancer. Dr. Hope Rugo: Thank you very much, and thanks for talking with me today. Dr. Monty Pal: You got it. And thanks a lot to our listeners today as well. You'll find links to all the studies we discussed today in the transcript of this episode. Finally, if you value the insights that you hear today on the ASCO Daily News Podcast, please rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinion of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:   Dr. Monty Pal @montypal Dr. Hope Rugo   @hoperugo Follow ASCO on social media:        ASCO on X  ASCO on Bluesky       ASCO on Facebook        ASCO on LinkedIn        Disclosures:     Dr. Monty Pal:    Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview   Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical   Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis   Dr. Hope Rugo:    Honoraria: Mylan/Viatris, Chugai Pharma   Consulting/Advisory Role: Napo Pharmaceuticals, Sanofi, Bristol Myer   Research Funding (Inst.): OBI Pharma, Pfizer, Novartis, Lilly, Merck, Daiichi Sankyo, AstraZeneca, Gilead Sciences, Hoffman La-Roche AG/Genentech, In., Stemline Therapeutics, Ambryx  

Join us as we dive into the latest advancements in HER2-positive breast cancer from SABCS 2025. In this episode, we discussed key studies including DESTINY Breast-11 and DESTINY Breast-05, highlighting their implications for neoadjuvant and adjuvant treatments. We also explored the HER2CLIMB-05 trial and the recent approval of TDXD with pertuzumab in frontline settings for metastatic HER2-positive disease. Special guest Dr. Harold Burstein from Dana-Farber Cancer Institute shared his insights on the evolving landscape of HER2-positive breast cancer treatment, including the importance of patient selection and the management of side effects like interstitial lung disease (ILD). Tune in for a comprehensive recap of the latest data, treatment algorithms, and how these advancements are changing the lives of patients with HER2-positive breast cancer. Don't forget to like, subscribe, and check out our other episodes for more updates on treatment options and conference highlights! Topics Covered: • DESTINY Breast-11 and its impact on neoadjuvant therapy • Insights from DESTINY Breast-05 on adjuvant treatment for high-risk residual disease • HER2CLIMB-05 trial findings and implications for metastatic disease • The role of T-DXd with pertuzumab in frontline settings • The PATINA trial and its significance for triple-positive metastatic breast cancer Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to like, subscribe, and check out our other episodes for more insights on treatment algorithms, recent approvals, and conference highlights! #SABCS2025 #HER2positive #DestinyTrials #OncologyBrothers #BreastCancer

The Patina reluctantly returns to the Guts to reach the city core.Cast: - Marathon Messenger is played by Penn Van Batavia. She can be found on Twitter at @acquiredchaste and in drag as horror king JOHN on Instagram at @john.is.risen. Penn is an indie TTRPG designer whose most recent work includes SLICE *IT* OUT, a grisly carving RPG about cutting pieces of yourself out to fit in. Check out faer other work at pennharper.itch.io. - Cassidy Shard is played by Sydney Whittington. She is our wonderful editor. She's also a contributing editor and occasional guest player for the Orpheus Protocol, a cosmic horror espionage actual play podcast. Find her on Twitter at @sydney_whitt. - Emma Blackwood is played by Cameron Robertson. Find her on Twitter at @midnightmusic13 and on Instagram at @reading_and_dreaming. Cameron is also a player on Tabletop Squadron, a Star Wars Edge of the Empire actual play podcast. - Birdie Foundling is played by Kit Adames. Find her on Twitter at @venusvultures. Kit is also a voice actor and writer on Elevator Pitch Podcast, a queer genre-hopping anthology podcast that can be accessed on Spotify and YouTube. - Our GM and narrator is Nick Robertson. Find him on Twitter at @alias58. Nick is also the GM for Tabletop Squadron and can also be found as a player on the Orpheus Protocol.Music & Sound Credits: - This podcast features the musical talents of Dora Violet and Arne Parrott. You can find Dora at facebook.com/doraviolett. You can find Arne at atptunes.com. - old radio Channel search sound effect by Garuda1982. Link & License. - Breezy city amb.wav by patchen. Link & License. - Ricochet metal 3.wav by CGEffex. Link & License. - Comets and Sparks by Sergey Chersmisinov. Link & License. - Endearing Curl by Blue Dot Sessions. Link & License.Art Credits: - The official artwork for this podcast was created by Rashed AlAkroka, who can be found on Instagram and Artstation @rashedjrs.Find Us Online: - Our Website - Twitter - Join our Patreon - Join our Discord

Das schöne Silberbesteck fürs Weihnachtsfest, die Schalen und Schüsseln oxidieren mit der Zeit. Es gibt aber ganz einfache Tipps, um sie im Nu fürs Weihnachtsfest aufzufrischen. Silberbesteck läuft weniger an, wenn es regelmässig benutzt wird. Besonders bei Eierspeisen sollte es jedoch nicht verwendet werden, da Eier das Silber angreifen. Oxidiertes Silber kann auf zwei Arten gereinigt werden: mechanisch mit Zahnpasta oder chemisch mit einem Hausmittel: • Die mechanische Reinigung mit Zahnpasta eignet sich besonders für verzierte Silbergegenstände, da die Patina in den Vertiefungen erhalten bleibt. • Für die chemische Reinigung werden heisses Wasser, Alufolie, Salz und ein Becken benötigt. Diese Methode ist einfach und effektiv, kann aber die Patina entfernen. • Nach der chemischen Reinigung erscheint das Silber komplett silbrig, ohne dunkle Schattierungen. Es dauert etwa ein halbes Jahr, bis die Tiefe der Verzierungen wieder sichtbar wird.

Tervetuloa luennolle suomalaisista kaduista ja niiden nimistä! Onko Kimmo ainoa joka ei pysty elämään tietämättömyydessä, mitkä ovat lahjoja joita on kiva saada, miksi Kimmolle pitää hankkia partakulkusia ja oletko ehtinyt käymään vielä joulumarkkinoilla? Minna ja Kimmo Radio Novan Aamussa arkisin klo 6-10!

Dr. Juan Carlos Samamé, oncólogo médico de Lima, Perú, y vicepresidente de la Latin American Breast Cancer Association (LABCA), recibe al Dr. Antonio Llombart Cussac, jefe de servicio en el Hospital Arnau de Vilanova y coordinador en la Universidad Cardenal Herrera en Valencia, España. Juntos nos hablan sobre lo mejor en cáncer de mama, presentado en el marco del Simposio de Cáncer de Mama de San Antonio 2025, celebrado del 9 al 12 de diciembre de 2025 en San Antonio, Texas, Estados Unidos.Cáncer de mama luminal:lidERA Breast Cancer [1]EPIK-B5 [2]Cáncer de mama HER2:PHERGain [3] CLEOPATRA[4]PATINA[5]HER2CLIMB-05[6]ALTTO[7]Referencias:Giredestrant vs standard-of-care endocrine therapy as adjuvant treatment for patients with estrogen receptor-positive, HER2-negative early breast cancer: Results from the global Phase III lidERA Breast Cancer trial. https://sabcs.org/events/general-session-1/. Presentación científica (Abstract GS1-10). Presentado en el marco del Simposio de Cáncer de Mama de San Antonio 2025, celebrado del 9 al 12 de diciembre de 2025 en San Antonio, Texas, Estados Unidos.De Laurentiis M., Ferreira A. M., Gligorov, J., y cols. (2025, diciembre 9–12). Alpelisib plus fulvestrant for PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer after a CDK4/6 inhibitor (EPIK-B5): Phase III, randomized, double-blind, placebo-controlled, multicenter study (Abstract RF7-02). Presentado en el marco del Simposio de Cáncer de Mama de San Antonio 2025, celebrado del 9 al 12 de diciembre de 2025 en San Antonio, Texas, Estados Unidos.Llombart-Cussac, A., Pérez-García, J., Ruiz-Borrego., y cols. Circulating tumor DNA (ctDNA) in human epidermal growth factor receptor 2-positive (HER2[+]) Early Breast Cancer (EBC): Translational analysis of PHERGain neoadjuvant tailored treatment study (Abstract GS1-06). Presentado en el marco del Simposio de Cáncer de Mama de San Antonio 2025, celebrado del 9 al 12 de diciembre de 2025 en San Antonio, Texas, Estados Unidos.Rinnerthaler, G., Gampenrieder, S. P., Pichler, A., y cols. Clinical predictors for first-line treatment duration in HER2-positive metastatic breast cancer: Results from the AGMT_MBC-Registry. AGMT_MBC-Registry study (Abstract PS5-01-04). Presentado en el marco del Simposio de Cáncer de Mama de San Antonio 2025, celebrado del 9 al 12 de diciembre de 2025 en San Antonio, Texas, Estados Unidos.Metzger, O., Mandrekar, S., & Dockter, T. (2025, December 9–12). Central nervous system outcomes from the Phase III PATINA trial (AFT-38) (Abstract RF4-01). Presentado en la San Antonio Breast Cancer Symposium (SABCS) 2025; del 09 al 12 de diciembre de 2025; San Antonio, Texas.Hamilton E., Curigliano G., Martin M., y cols (2025). HER2CLIMB-05: A randomized, double-blind, phase 3 study of tucatinib versus placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic breast cancer. Abstract GS1-01. Presentado en el marco del Simposio de Cáncer de Mama de San Antonio 2025, celebrado del 9 al 12 de diciembre de 2025 en San Antonio, Texas, Estados Unidos.Lambertini M, Samy F, Agostinetto E y cols. Adjuvant aromatase inhibitor or tamoxifen in patients with hormone receptor-positive/HER2-positive early breast cancer: An exploratory analysis from the ALTTO (BIG 2-06) trial. Abstract #GS1-03. Presentado en la San Antonio Breast Cancer Symposium (SABCS) 2025; del 09 al 12 de diciembre de 2025; San Antonio, Texas. Abstract GS1-09.

The Patina has a tense negotiation and the city fights back.Cast: - Marathon Messenger is played by Penn Van Batavia. She can be found on Twitter at @acquiredchaste and in drag as horror king JOHN on Instagram at @john.is.risen. Penn is an indie TTRPG designer whose most recent work includes SLICE *IT* OUT, a grisly carving RPG about cutting pieces of yourself out to fit in. Check out faer other work at pennharper.itch.io. - Cassidy Shard is played by Sydney Whittington. She is our wonderful editor. She's also a contributing editor and occasional guest player for the Orpheus Protocol, a cosmic horror espionage actual play podcast. Find her on Twitter at @sydney_whitt. - Emma Blackwood is played by Cameron Robertson. Find her on Twitter at @midnightmusic13 and on Instagram at @reading_and_dreaming. Cameron is also a player on Tabletop Squadron, a Star Wars Edge of the Empire actual play podcast. - Birdie Foundling is played by Kit Adames. Find her on Twitter at @venusvultures. Kit is also a voice actor and writer on Elevator Pitch Podcast, a queer genre-hopping anthology podcast that can be accessed on Spotify and YouTube. - Our GM and narrator is Nick Robertson. Find him on Twitter at @alias58. Nick is also the GM for Tabletop Squadron and can also be found as a player on the Orpheus Protocol.Music & Sound Credits: - This podcast features the musical talents of Dora Violet and Arne Parrott. You can find Dora at facebook.com/doraviolett. You can find Arne at atptunes.com. - old radio Channel search sound effect by Garuda1982. Link & License. - "Sekalaiset Miscellaneous » Sähköisiä räsähdyksiä / Electrical, short crackling, cracking, hissing sounds, like short-circuit, electric fault or electric shock, a close sound" by YleArkisto. Link & License. - "Ricochet" by ValhallaProject. Link & License. - Big Water by Sergey Cheremisinov. Link & License. - Lac des Arcs by Julia Kent. Link & License.Art Credits: - The official artwork for this podcast was created by Rashed AlAkroka, who can be found on Instagram and Artstation @rashedjrs.Find Us Online: - Our Website - Twitter - Join our Patreon - Join our Discord

Video zur Episode Text-/Audio-/Videokommentar einreichen HS-Hörer:innen im Slack treffen Aus der Preshow Guten Abend schreibt der youtube, aus der Badewanne podcasten, Nix HS Workshops Neue Workshops geöffnet: Fotoprojekte & Großformat HS Workshop-Newsletter Testimonials von Workshopteilnehmern gesucht Alte Newsletter funktionieren nicht mehr, bitte neu anmelden Neue Newsletter Statt Werbung DANKE an alle Spender #hshi / #hsnachtrag … „#921 – Podcast mit Patina“ weiterlesen

The Patina runs into more trouble as they try to reach the city core.Cast: - Marathon Messenger is played by Penn Van Batavia. She can be found on Twitter at @acquiredchaste and in drag as horror king JOHN on Instagram at @john.is.risen. Penn is an indie TTRPG designer whose most recent work includes SLICE *IT* OUT, a grisly carving RPG about cutting pieces of yourself out to fit in. Check out faer other work at pennharper.itch.io. - Cassidy Shard is played by Sydney Whittington. She is our wonderful editor. She's also a contributing editor and occasional guest player for the Orpheus Protocol, a cosmic horror espionage actual play podcast. Find her on Twitter at @sydney_whitt. - Emma Blackwood is played by Cameron Robertson. Find her on Twitter at @midnightmusic13 and on Instagram at @reading_and_dreaming. Cameron is also a player on Tabletop Squadron, a Star Wars Edge of the Empire actual play podcast. - Birdie Foundling is played by Kit Adames. Find her on Twitter at @venusvultures. Kit is also a voice actor and writer on Elevator Pitch Podcast, a queer genre-hopping anthology podcast that can be accessed on Spotify and YouTube. - Our GM and narrator is Nick Robertson. Find him on Twitter at @alias58. Nick is also the GM for Tabletop Squadron and can also be found as a player on the Orpheus Protocol.Music & Sound Credits: - This podcast features the musical talents of Dora Violet and Arne Parrott. You can find Dora at facebook.com/doraviolett. You can find Arne at atptunes.com. - old radio Channel search sound effect by Garuda1982. Link & License. - Metal_heavy_punch_with_crunch_and_glass_debris_sounds_08242024 by Artninja. Link & License. - Whistle, Finger, Long, A.wav by InspectorJ. Link & License. - explosive_punchy_rock_impacts_fate_stay_night_HF_inspired_11162025 by Artninja. Link & License. - gunshot.wav by mark646. Link & License. - Running Eiskrokodil (ID 01) - Remastered by Lobo Loco. Link & License. - Recognize Greatness by The Oracle Of St. Vincent. Link & License.Art Credits: - The official artwork for this podcast was created by Rashed AlAkroka, who can be found on Instagram and Artstation @rashedjrs.Find Us Online: - Our Website - Twitter - Join our Patreon - Join our Discord

If you stop by PATINA in South Minneapolis, you might get a chance to meet Perry. How did this local cat become a draw for shoppers at the popular business? Find out from Karin Tappero-Director of Retail Operations for PATINA , and Rachel Traver who is Perry's Momma!

The Patina reunites and figures out their next steps during the Battle of Sasnak Traveling.Cast: - Marathon Messenger is played by Penn Van Batavia. She can be found on Twitter at @acquiredchaste and in drag as horror king JOHN on Instagram at @john.is.risen. Penn is an indie TTRPG designer whose most recent work includes SLICE *IT* OUT, a grisly carving RPG about cutting pieces of yourself out to fit in. Check out faer other work at pennharper.itch.io. - Cassidy Shard is played by Sydney Whittington. She is our wonderful editor. She's also a contributing editor and occasional guest player for the Orpheus Protocol, a cosmic horror espionage actual play podcast. Find her on Twitter at @sydney_whitt. - Emma Blackwood is played by Cameron Robertson. Find her on Twitter at @midnightmusic13 and on Instagram at @reading_and_dreaming. Cameron is also a player on Tabletop Squadron, a Star Wars Edge of the Empire actual play podcast. - Birdie Foundling is played by Kit Adames. Find her on Twitter at @venusvultures. Kit is also a voice actor and writer on Elevator Pitch Podcast, a queer genre-hopping anthology podcast that can be accessed on Spotify and YouTube. - Our GM and narrator is Nick Robertson. Find him on Twitter at @alias58. Nick is also the GM for Tabletop Squadron and can also be found as a player on the Orpheus Protocol.Music & Sound Credits: - This podcast features the musical talents of Dora Violet and Arne Parrott. You can find Dora at facebook.com/doraviolett. You can find Arne at atptunes.com. - old radio Channel search sound effect by Garuda1982. Link & License. - 12120 collapsing building.wav by Robinhood76. Link & License. - Tramontana by Julia Kent. Link & License. - Glueworm Evening Blues (ID 994) by Lobo Loco. Link & License.Art Credits: - The official artwork for this podcast was created by Rashed AlAkroka, who can be found on Instagram and Artstation @rashedjrs.Find Us Online: - Our Website - Twitter - Join our Patreon - Join our Discord

The Patina fight their way back to each other and do some heroics along the way.Cast: - Marathon Messenger is played by Penn Van Batavia. She can be found on Twitter at @acquiredchaste and in drag as horror king JOHN on Instagram at @john.is.risen. Penn is an indie TTRPG designer whose most recent work includes SLICE *IT* OUT, a grisly carving RPG about cutting pieces of yourself out to fit in. Check out faer other work at pennharper.itch.io. - Cassidy Shard is played by Sydney Whittington. She is our wonderful editor. She's also a contributing editor and occasional guest player for the Orpheus Protocol, a cosmic horror espionage actual play podcast. Find her on Twitter at @sydney_whitt. - Emma Blackwood is played by Cameron Robertson. Find her on Twitter at @midnightmusic13 and on Instagram at @reading_and_dreaming. Cameron is also a player on Tabletop Squadron, a Star Wars Edge of the Empire actual play podcast. - Birdie Foundling is played by Kit Adames. Find her on Twitter at @venusvultures. Kit is also a voice actor and writer on Elevator Pitch Podcast, a queer genre-hopping anthology podcast that can be accessed on Spotify and YouTube. - Our GM and narrator is Nick Robertson. Find him on Twitter at @alias58. Nick is also the GM for Tabletop Squadron and can also be found as a player on the Orpheus Protocol.Music & Sound Credits: - This podcast features the musical talents of Dora Violet and Arne Parrott. You can find Dora at facebook.com/doraviolett. You can find Arne at atptunes.com. - old radio Channel search sound effect by Garuda1982. Link & License. - 12120 collapsing building.wav by Robinhood76. Link & License. - Riot Crowd Immersed in 5.1 Take 1 by MrProfDrDickweed. Link & License. - Sword Shing 19 by Department64. Link & License. - Rocky Roads by Stefano Vita. Link & License. - Rush by Crowander. Link & License.Art Credits: - The official artwork for this podcast was created by Rashed AlAkroka, who can be found on Instagram and Artstation @rashedjrs.Find Us Online: - Our Website - Twitter - Join our Patreon - Join our Discord

Drs. Waks and Lynce review the PATINA trial, which showed that adding a CDK4/6 inhibitor to HER2-targeted and endocrine therapy improved progression-free survival in triple-positive breast cancer, shaping how this subgroup may be managed.

Dina Aronson is a writer, editor, and pro-age advocate who is passionate about shining a light on midlife women and reframing the cultural conversation around aging. A former attorney, law firm manager, and founder of a legal search consultancy, she pivoted careers at 51 after realizing how little content reflected her own evolving midlife experience. She began freelancing for startups focused on women over 40. Along the way, she founded the Patina blog, now a Substack newsletter called Patina with Dina Aronson, where she explores topics related to aging through her midlife lens. Dina is the coeditor of Midlife Private Parts: Revealing Essays that Will Change the Way You Think About Age, a soulful, unfiltered collection of stories that speak to what it really feels like to be a midlife woman in the world today.  She sits on the Governing Board of the nonprofit America Needs You and on the Influencer Council of the nonprofit Uncommon Threads. Dina lives between New York City and Miami with her husband and is the proud stepmother of two grown sons. In today's episode, Nada talks with Dina about her new book of essays, “Midlife Private Parts.” Dina pursued this project to honor her mother's memory and legacy. Dina shares how she and co-author Dina Alvarez collected intimate stories about midlife with the hope that readers will feel less alone as they navigate their respective journeys. From learning to be vulnerable to giving up the need for control, the two reflect on the many aspects of life that become liberated in the middle third Check out “Midlife Private Parts” for more information on Dina's work. Follow on IG: @patina_life.  Please follow us at @thisislibertyroad on Instagram; we want to share and connect with you and hear your thoughts and comments. Please rate and review this podcast. It helps to know if these conversations inspire and equip you to consider your possibilities and lean into your future with intention.

This dialogue highlights the significance of creating meaningful connections and the joy that comes from building impactful connections and fostering a culture of inclusion within personal and professional relationships. They discuss the power of rituals and micro habits to guide you through each day and the beautiful connection between your physical environmentand your energy. Chapters00:00 Welcome01:27 A Word From Our Sponsor02:27 Soulful and Corny Connections03:24 Space to Feel06:36 Set the Tone for Your Day11:25 Send Loving Energy Into Your Day15:13 Rituals to Guide Your Day21:18 My Soul Nest is my Sanctuary  26:07 Beauty Through the Pain31:17 Follow Your Energy to Find Your Moments36:29 Natural Authentic Connection44:41 When Things No Longer Fit50:23 Still Relevant After 5053:15 Appreciating Relief55:29 Simple Pleasures in Choosing Yourself59:43 What Wants to be Awakened Within You More about Michelle Herndon Michelle Herndon is a prominent leader in her industry. She is best known for her meaningful insights, mentorship andleadership.  Michelle began her career in hospitality at the famed Patina restaurant in Los Angeles.  A very special time in the culinary world which has had great impact on her personal and professional life. Before joining BOKA Restaurant Group, Michelle had an illustrious career including time spent in HR staffing, Diversity & Inclusion training for Limited Brands. Over the last decade Michelle has enjoyed a successful relationship with BOKA Restaurant Group as Director of PrivateEvents. Michelle has collaborated and created revenue generating private events programs for six restaurant openings for BOKA in the Chicago area. She is currently the Director of Culture + Community for BOKA Group, where she is furthering diversity programs and services within the company-including creating and leading mentorship program for People of Color and within the LGBTQ+ community. She is known for her ability to bridge differences and create impactful connections within her company. She leads the recruiting department for the entire group, where identifying diverse talent while ensuring equity is her company's mission.  Michelle graduated from the University of Illinois/University of Barcelona and received a Bachelor of Arts, Spanish. She hasalso earned her Diversity, Equity and Inclusion Certification from Cornell University. She additionally spends time professional lifestyle coaching for her currently growing project SoulNest. Connect with MichelleInstagram @TheMichelleHerndon A Moment of Gratitude for our sponsor.⁠ Michele AikensConnect with Melanie⁠⁠Work with Melanie⁠⁠Download Joy Journal⁠⁠⁠⁠Radical Love Book

Este boletim traz um resumo das principais notícias do dia na análise de Samuel Possebon, editor chefe da TELETIME.TELETIME é a publicação de referência para quem acompanha o mercado de telecomunicações, tecnologia e Internet no Brasil. Uma publicação independente dedicada ao debate aprofundado e criterioso das questões econômicas, regulatórias, tecnológicas, operacionais e estratégicas das empresas do setor. Se você ainda não acompanha a newsletter TELETIME, inscreva-se aqui (shorturl.at/juzF1) e fique ligado no dia a dia do mercado de telecom. É simples e é gratuito.Você ainda pode acompanhar TELETIME nas redes sociais:Linkedin: shorturl.at/jGKRVFacebook: https://www.facebook.com/Teletime/ Google News: shorturl.at/kJU35Ou entre em nosso canal no Telegram: https://t.me/teletimenews Hosted on Acast. See acast.com/privacy for more information.

The Patina shines in the Championship parade as political dealings behind closed doors cause unforeseen chaos.Cast: - Marathon Messenger is played by Penn Van Batavia. She can be found on Twitter at @acquiredchaste and in drag as horror king JOHN on Instagram at @john.is.risen. Penn is an indie TTRPG designer whose most recent work includes SLICE *IT* OUT, a grisly carving RPG about cutting pieces of yourself out to fit in. Check out faer other work at pennharper.itch.io. - Cassidy Shard is played by Sydney Whittington. She is our wonderful editor. She's also a contributing editor and occasional guest player for the Orpheus Protocol, a cosmic horror espionage actual play podcast. Find her on Twitter at @sydney_whitt. - Emma Blackwood is played by Cameron Robertson. Find her on Twitter at @midnightmusic13 and on Instagram at @reading_and_dreaming. Cameron is also a player on Tabletop Squadron, a Star Wars Edge of the Empire actual play podcast. - Birdie Foundling is played by Kit Adames. Find her on Twitter at @venusvultures. Kit is also a voice actor and writer on Elevator Pitch Podcast, a queer genre-hopping anthology podcast that can be accessed on Spotify and YouTube. - Our GM and narrator is Nick Robertson. Find him on Twitter at @alias58. Nick is also the GM for Tabletop Squadron and can also be found as a player on the Orpheus Protocol.Music & Sound Credits: - This podcast features the musical talents of Dora Violet and Arne Parrott. You can find Dora at facebook.com/doraviolett. You can find Arne at atptunes.com. - old radio Channel search sound effect by Garuda1982. Link & License. - WALLA Ballpark Applause Short 05 by AshFox. Link & License. - WALLA Ballpark Applause Short 01 by AshFox. Link & License. - Cardiff Indoor Market by odilonmarcenaro. Link & License. - Riot Crowd Immersed in 5.1 Take 1 by MrProfDrDickweed. Link & License. - Sleepers by Sergey Cheremisinov. Link & License. - Death Valley (ID 1001) - Remastered by Lobo Loco. Link & License.Art Credits: - The official artwork for this podcast was created by Rashed AlAkroka, who can be found on Instagram and Artstation @rashedjrs.Find Us Online: - Our Website - Twitter - Join our Patreon - Join our Discord

Nat and Marc are back, but Nat's back?… well it's not great. Marc has broken his scan and shop virginity and is still very keen to roll the dice on out of date produce. And the big debate of Bourbon vs Ginger Nut… They also go a bit baaaarmy! Enjoy! xx Also shoutout to https://www.instagram.com/samnixon18 Please subscribe, follow, and leave a review. xxx You can find us in all places here; ⁠⁠⁠https://podfollow.com/lifewithnat/view⁠⁠⁠ We're on Facebook: ⁠⁠⁠https://www.facebook.com/lifewithnatpod⁠⁠⁠ Nat's insta: ⁠⁠@natcass1⁠⁠ Neice's insta: ⁠@natsnieces⁠ Tony's insta: ⁠@tonycass68⁠ Linny's insta: ⁠@auntielinny.lwn⁠ THE BIG CHRISTMAS LIVE SHOW 7th December ⁠⁠⁠⁠- claphamgrand.com/event/live-with-nat-at-christmas/⁠⁠ The tiny warm-up shows 4th Nov - Dixon Studio, Palace Theatre, Southend - ⁠⁠www.trafalgartickets.com/palace-theatre-southend/en-GB/event/other/live-with-nat-work-in-progress-tickets⁠⁠ 6th Nov - Hat Factory, Luton - ⁠⁠http://www.culturetrust.com/whats-on/live-nat-work-progress⁠⁠ 16th Nov - Hawth Studio, The Hawth Theatre, Crawley - ⁠⁠https://www.parkwoodtheatres.co.uk/the-hawth/whats-on/live-with-nat-work-in-progress⁠⁠ Book Club: Bob Mortimer's Autobiography "And Away" ⁠https://amzn.eu/d/begUIQ3⁠ Nat's solo chats - any rants always welcome!  Scraping the Barrel - SCAN AND SHOP VIRGIN NO LONGER! Marc's still adamant that days old salad from a takeaway is an ideal packed lunch - what's the maddest thing you've pack for lunch? Bonce vs list! - Are you a list maker? Always collecting for Nostalgia Fest! What's brewing with the Nieces - are we all skipping the end of summer, all of autumn and going straight to Christmas? Group chat ettiquette - the “happy birthday” that makes everyone else's look like they're tagging on! Things we're nagging with Linny about - Chilled walks gone wrong! Getting locked out when you're in a hurry and everything becoming a right faff The Tony talks chatter - Keep your DIY questions coming, also open to some saucy two paragraph stories for Tony to read out at the Southend show - think cheeky postcards (both in tone and length)! Can we make Tony an influencer and get him any freebies?  AOB - Housecoats… lets bring them back?!  Georgina's Fact - What cat have you let out of the bag? Have you been scammed? A 'Keep It Light Media' Production Sales, advertising, and general enquiries: ⁠⁠⁠hello@keepitlightmedia.com⁠⁠⁠ SHOW INFO: Life with Nat - it's me! Natalie Cassidy and I'll be chatting away to family, friends and most importantly YOU. I want to pick people's brains on the subjects that I care about- whether that's where all the odd socks go, weight and food or kids on phones. Each week I will be letting you into my life as i chat about my week, share my thoughts on the mundane happenings as well as the serious. I have grown up in the public eye and have never changed because of it. Life with Nat is the podcast for proper people. Come join the community. ♥️ Learn more about your ad choices. Visit megaphone.fm/adchoices

The Patina meets back up while they await the judges final scores for the X Bike Championship Finals.Cast: - Marathon Messenger is played by Penn Van Batavia. She can be found on Twitter at @acquiredchaste and in drag as horror king JOHN on Instagram at @john.is.risen. Penn is an indie TTRPG designer whose most recent work includes SLICE *IT* OUT, a grisly carving RPG about cutting pieces of yourself out to fit in. Check out faer other work at pennharper.itch.io. - Cassidy Shard is played by Sydney Whittington. She is our wonderful editor. She's also a contributing editor and occasional guest player for the Orpheus Protocol, a cosmic horror espionage actual play podcast. Find her on Twitter at @sydney_whitt. - Emma Blackwood is played by Cameron Robertson. Find her on Twitter at @midnightmusic13 and on Instagram at @reading_and_dreaming. Cameron is also a player on Tabletop Squadron, a Star Wars Edge of the Empire actual play podcast. - Birdie Foundling is played by Kit Adames. Find her on Twitter at @venusvultures. Kit is also a voice actor and writer on Elevator Pitch Podcast, a queer genre-hopping anthology podcast that can be accessed on Spotify and YouTube. - Our GM and narrator is Nick Robertson. Find him on Twitter at @alias58. Nick is also the GM for Tabletop Squadron and can also be found as a player on the Orpheus Protocol.Music & Sound Credits: - This podcast features the musical talents of Dora Violet and Arne Parrott. You can find Dora at facebook.com/doraviolett. You can find Arne at atptunes.com. - old radio Channel search sound effect by Garuda1982. Link & License. - WALLA Ballpark Applause Short 05 by AshFox. Link & License. - bike_horn by MiscPractice. Link & License. - VEHSirn_Police Car Siren.Synthesized.Dry 2_EM.wav by newlocknew. & License. - Camera Flashing.wav by 221227. Link & License. - Tools in a tool box by OpenWillem. Link & License. - Fast Fire Flare Whoosh 1(6lrs).wav by newlocknew. Link & License. - Unexpected Hoedown In Bagging Area by Doctor Turtle. Link & License.Art Credits: - The official artwork for this podcast was created by Rashed AlAkroka, who can be found on Instagram and Artstation @rashedjrs.Find Us Online: - Our Website - Twitter - Join our Patreon - Join our Discord

Discover why titanium watch bands offer unmatched durability while being 45% lighter than steel, and how leather naturally conforms to your wrist, developing a unique patina. Both hypoallergenic materials provide exceptional comfort for everyday wear. Learn more at https://robustgoods.com/collections/samsung-galaxy-watch-ultra-bands RobustGoods City: Helsinki Address: 6 Simonkatu Website: https://robustgoods.com/

Women over 40 comprise 25% of the U.S. population, yet they remain significantly underrepresented in popular culture and the media. Dina Alvarez and Dina Aronson set out to change that with their bold new anthology, Midlife Private Parts: Revealing Essays That Will Change the Way You Think About Age. It is a deeply moving collection of soulful essays that speak to what it really feels like to move through the world as a midlife woman and beyond. It is a rallying cry to embrace midlife unapologetically, and a powerful reminder that you are not going through it alone.Dina Alvarez started her writing career as a freelancer for Big Apple Parent in New York City covering education, local politics, and lifestyle. She later co-founded SomosPadres, the first and only bilingual parenting publication for Hispanic families in New York City. Dina currently works for a financial firm and continues to write in her spare time with a focus on creative nonfiction pieces. Dina is an avid reader and lover of anthologies, particularly those that tell women's stories. Dina is the mother of two adult sons and a native New Yorker. She continues to call the city home where she lives with her husband and youngest son.Dina Aronson is a writer, editor and pro-age advocate who is passionate about shining a light on midlife women and reframing the cultural conversation around aging. She began her career as an attorney, later founding a legal search consultancy, but pivoted as she approached midlife and couldn't find relevant content that reflected her experience. She began freelancing for start-ups aimed at the forty and above woman, and founded the Patina blog, now a Substack newsletter called Patina with Dina Aronson, where she explores topics in and around aging through her midlife lens. She has two grown stepsons, and currently resides between New York City and Miami with her husband.Midlife Private Parts: Revealing Essays that Will Change the Way You Think About Age (June 24, 2025, Regalo Press)Learn more: www.midlifeprivateparts.comIG handles: @patina_life and @thewritestyleshttps://substack.com/@patinawithdinaaronson https://open.substack.com/pub/dinaalvarez

Episode 4 digs into the intersection of pressure x progress – whether in collecting watches or building Collected. Tim and Zach start with the story of a rare 1966 Seamaster picked up for $3,000, breaking down why its lume, bracelet, and design details still rival the tool watches of Tudor and Rolex from the same era. From there, they get into how the Collected team is scaling infrastructure through automation, testing, and dealer-first tools, while also unpacking the reality of 39% tariffs on imports and the potential ripple effects for pricing, risk, and supply in the months ahead. They close with a candid look at why clarity of brand positioning is as crucial for investors as it is for dealers. It's a conversation that moves from case patina to market strategy, with plenty of lessons in between.

Without Your Head: Alan Maxson of Monster Island, Godzilla & more!Monster suit and motion capture actor Alan Maxson of films like The Gingerweed Man, Puppetmaster's Blade, Rock Steady of Ninja Turtles Blood Brothers, King Ghidorah in Godzilla King of the Monsters and most recently the Orang Ikan in Monster Island now playing Shudder!Alan is also a filmmaker with his own movies Patina and Alien Planet!

The Patina has planned and surprise meetings with Sasnak Councilors.Cast: - Marathon Messenger is played by Penn Van Batavia. She can be found on Twitter at @acquiredchaste and in drag as horror king JOHN on Instagram at @john.is.risen. Penn is an indie TTRPG designer whose most recent work includes SLICE *IT* OUT, a grisly carving RPG about cutting pieces of yourself out to fit in. Check out faer other work at pennharper.itch.io. - Cassidy Shard is played by Sydney Whittington. She is our wonderful editor. She's also a contributing editor and occasional guest player for the Orpheus Protocol, a cosmic horror espionage actual play podcast. Find her on Twitter at @sydney_whitt. - Emma Blackwood is played by Cameron Robertson. Find her on Twitter at @midnightmusic13 and on Instagram at @reading_and_dreaming. Cameron is also a player on Tabletop Squadron, a Star Wars Edge of the Empire actual play podcast. - Birdie Foundling is played by Kit Adames. Find her on Twitter at @venusvultures. Kit is also a voice actor and writer on Elevator Pitch Podcast, a queer genre-hopping anthology podcast that can be accessed on Spotify and YouTube. - Our GM and narrator is Nick Robertson. Find him on Twitter at @alias58. Nick is also the GM for Tabletop Squadron and can also be found as a player on the Orpheus Protocol.Music & Sound Credits: - This podcast features the musical talents of Dora Violet and Arne Parrott. You can find Dora at facebook.com/doraviolett. You can find Arne at atptunes.com. - old radio Channel search sound effect by Garuda1982. Link & License. - WALLA Ballpark Applause Short 01 by AshFox. Link & License. - Ahooga vintage car horn, remix of craigsmith's Freesound 480002.wav by Timbre. Link & License. - bike_horn by MiscPractice. Link & License. - toaster oven or lift/elevator bell by azumarill. Link & License. - United Voyagers by Sergey Chereminisov. Link & License.Art Credits: - The official artwork for this podcast was created by Rashed AlAkroka, who can be found on Instagram and Artstation @rashedjrs.Find Us Online: - Our Website - Twitter - Join our Patreon - Join our Discord

Marathon and Birdie make some impulsive decisions and the Patina races their hearts out.Cast: - Marathon Messenger is played by Penn Van Batavia. She can be found on Twitter at @acquiredchaste and in drag as horror king JOHN on Instagram at @john.is.risen. Penn is an indie TTRPG designer whose most recent work includes SLICE *IT* OUT, a grisly carving RPG about cutting pieces of yourself out to fit in. Check out faer other work at pennharper.itch.io. - Cassidy Shard is played by Sydney Whittington. She is our wonderful editor. She's also a contributing editor and occasional guest player for the Orpheus Protocol, a cosmic horror espionage actual play podcast. Find her on Twitter at @sydney_whitt. - Emma Blackwood is played by Cameron Robertson. Find her on Twitter at @midnightmusic13 and on Instagram at @reading_and_dreaming. Cameron is also a player on Tabletop Squadron, a Star Wars Edge of the Empire actual play podcast. - Birdie Foundling is played by Kit Adames. Find her on Twitter at @venusvultures. Kit is also a voice actor and writer on Elevator Pitch Podcast, a queer genre-hopping anthology podcast that can be accessed on Spotify and YouTube. - Our GM and narrator is Nick Robertson. Find him on Twitter at @alias58. Nick is also the GM for Tabletop Squadron and can also be found as a player on the Orpheus Protocol.Music & Sound Credits: - This podcast features the musical talents of Dora Violet and Arne Parrott. You can find Dora at facebook.com/doraviolett. You can find Arne at atptunes.com. - old radio Channel search sound effect by Garuda1982. Link & License. - Cardiff Indoor Market by odilonmarcenaro. Link & License. - Hypocritopotamus by Doctor Turtle. Link & License. - Today's Special: Jam Tomorrow by Doctor Turtle. Link & License. - Remember Alexis Zorbas (ID 1340) by Lobo Loco. Link & License.Art Credits: - The official artwork for this podcast was created by Rashed AlAkroka, who can be found on Instagram and Artstation @rashedjrs.Find Us Online: - Our Website - Twitter - Join our Patreon - Join our Discord

Caroline and Liz welcome New York-based designer and author Brittany Bromley, known for her traditional interiors with layered patterns. Brittany shares insights from her new book, 'Relaxed Elegance,' and the inspiration behind her use of antique aesthetics mixed with luxurious details. Brittany also discusses her own home renovation and her design process, including the courageous use of patterns, colors, and textures in her projects. From transforming neglected homes to crafting customized room designs, Bromley's work reflects a mix of elegance and lived-in comfort, tailored to the personalities and needs of her clients. What You'll Hear This Episode: 00:00 Introduction to the Podcast 00:34 Meet Brittany Bromley: Designer and Author 01:18 Brittany's Home: A Designer's Vision 04:13 The Dining Room Transformation 12:29 The Art of Pattern Mixing 24:37 Bridge Hampton Residence: Humor and Tradition 27:19 Designing Double-Height Living Rooms 31:54 The Impact of a Large Window 32:20 Incorporating Color in Neutral Spaces 32:54 Choosing Muted Colors 34:09 The Role of Patterns and Textures 37:19 The Evolution of Textile Design 39:34 The Versatility of Natural Fiber Rugs 40:58 Creating Relaxed Elegance 42:11 The Importance of Patina and Layering 43:42 Using Marble in Kitchens 48:46 Balancing Cool and Warm Colors 51:58 Designing for Different Locations 53:39 The Rise of Performance Textiles 55:59 Conclusion and Final Thoughts Learn more about your ad choices. Visit megaphone.fm/adchoices

Drs. Callahan and Yuan discuss data presented at ASCO 2025 on DESTINY-Breast09, PATINA, and MINI Trial, the utility of PFS-2 as an endpoint, and sequencing of treatments after first-line therapy.

The Patina spends quality time in pairs during their last bit of free time.Cast: - Marathon Messenger is played by Penn Van Batavia. She can be found on Twitter at @acquiredchaste and in drag as horror king JOHN on Instagram at @john.is.risen. Penn is an indie TTRPG designer whose most recent work includes SLICE *IT* OUT, a grisly carving RPG about cutting pieces of yourself out to fit in. Check out faer other work at pennharper.itch.io. - Cassidy Shard is played by Sydney Whittington. She is our wonderful editor. She's also a contributing editor and occasional guest player for the Orpheus Protocol, a cosmic horror espionage actual play podcast. Find her on Twitter at @sydney_whitt. - Emma Blackwood is played by Cameron Robertson. Find her on Twitter at @midnightmusic13 and on Instagram at @reading_and_dreaming. Cameron is also a player on Tabletop Squadron, a Star Wars Edge of the Empire actual play podcast. - Birdie Foundling is played by Kit Adames. Find her on Twitter at @venusvultures. Kit is also a voice actor and writer on Elevator Pitch Podcast, a queer genre-hopping anthology podcast that can be accessed on Spotify and YouTube. - Our GM and narrator is Nick Robertson. Find him on Twitter at @alias58. Nick is also the GM for Tabletop Squadron and can also be found as a player on the Orpheus Protocol.Music & Sound Credits: - This podcast features the musical talents of Dora Violet and Arne Parrott. You can find Dora at facebook.com/doraviolett. You can find Arne at atptunes.com. - old radio Channel search sound effect by Garuda1982. Link & License. - Challk Writing - Slow.wav by PsychoPancake. Link & License. - Declaration of My Love by Squire Tuck. Link & License. - That Guy's Sky Is Way Too High (long version) by Doctor Turtle. Link & License. - NEONBULA.mp3 by P C III. Link & License.Art Credits: - The official artwork for this podcast was created by Rashed AlAkroka, who can be found on Instagram and Artstation @rashedjrs.Find Us Online: - Our Website - Twitter - Join our Patreon - Join our Discord

This week the boys sit down talk about the newly crowned Stanley Cup champion Florida Panthers, a little football and basketball. Then a nice Father's Day recap. We also touched on the conflict with Iran and Israel on the current events side of things. This all went down while we enjoyed the recently released year of the snake from Rocky PatelPatrol Gone Wild brings us a breakdown of one of the LA riot clips, a taser deployment, and a criminal with more than questionable court room attire.Caleb brings us news this week with a release announcement from Cavalier. A new collab from Patina and Viso Horny. Then a new expression from YellowstoneCigar: Rocky Patel Year Of The SnakeWhiskey: Catchers RyeA huge thank you to our show sponsors Crowned Heads Cigars, Dunbarton Tobacco and Trust, and Small Batch Cigars! Make sure you're checking them out for all of your cigar needs!https://www.crownedheads.comhttps://www.dunbartoncigars.comhttps://www.smallbatchcigar.comUse Code "HERF" For 10% off your order (Some Exclusions Apply) SUBSCRIBE TO OUR YOUTUBE CHANNEL AND WATCH ALL OF OUR EPISODES IN STUDIO!Join The After Herf Show on Patreon Now!Patreon: https://www.patreon.com/DownToHerfPodcastVisit our Social Media Pages for News and More!Instagram: https://www.instagram.com/downtoherfpodcast/Facebook: https://www.facebook.com/downtoherfpodcast/

This week on Episode 393, the boys gear up for Blend & Barrel this Thursday and a sizzling private dinner with Skip Martin on July 5th. Mike dives into a wild takedown by Simply Stogies—apparently their aftershow is better than the interview! We cover massive stories: U.S. strikes Iran's nuclear site, Tesla drops robotaxis in Austin, and Kevin Durant's shocking trade to Houston. Plus, Nicaragua slams the brakes with new speed limits, Davidoff slows production, and spicy new cigars from Patina and 601 La Bomba. Two reviews. One warhead. All hustle.

The Patina wraps up their heist at Ramp Girl HQ.Cast: - Marathon Messenger is played by Penn Van Batavia. She can be found on Twitter at @acquiredchaste and in drag as horror king JOHN on Instagram at @john.is.risen. Penn is an indie TTRPG designer whose most recent work includes SLICE *IT* OUT, a grisly carving RPG about cutting pieces of yourself out to fit in. Check out faer other work at pennharper.itch.io. - Cassidy Shard is played by Sydney Whittington. She is our wonderful editor. She's also a contributing editor and occasional guest player for the Orpheus Protocol, a cosmic horror espionage actual play podcast. Find her on Twitter at @sydney_whitt. - Emma Blackwood is played by Cameron Robertson. Find her on Twitter at @midnightmusic13 and on Instagram at @reading_and_dreaming. Cameron is also a player on Tabletop Squadron, a Star Wars Edge of the Empire actual play podcast. - Birdie Foundling is played by Kit Adames. Find her on Twitter at @venusvultures. Kit is also a voice actor and writer on Elevator Pitch Podcast, a queer genre-hopping anthology podcast that can be accessed on Spotify and YouTube. - Our GM and narrator is Nick Robertson. Find him on Twitter at @alias58. Nick is also the GM for Tabletop Squadron and can also be found as a player on the Orpheus Protocol.Music & Sound Credits: - This podcast features the musical talents of Dora Violet and Arne Parrott. You can find Dora at facebook.com/doraviolett. You can find Arne at atptunes.com. - old radio Channel search sound effect by Garuda1982. Link & License. - Pampa Salitrera » Stones tossed in the desert by Diegolar. Link & License. - fax.wav by LG. Link & License. - Labyrinth by Sergey Cheremisinov. Link & License. - A Hard Reality by The Oracle Of St. Vincent. Link & License. - What Is It I Know by The Oracle Of St. Vincent. Link & License.Art Credits: - The official artwork for this podcast was created by Rashed AlAkroka, who can be found on Instagram and Artstation @rashedjrs.Find Us Online: - Our Website - Twitter - Join our Patreon - Join our Discord